Of these drugs, we identified several DNA–protein kinase (DNA-PK) inhibitors that enhanced MHC-I expression levels, sensitized melanoma cells to T cell–mediated killing in vitro, and enhanced the ability of DCs to activate tumor-reactive T cells including NU7441, NU7026, and KU-0060648. Here, PRKDC is linked to melanoma.